{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:59:34Z","timestamp":1791302374315,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.intimp.2024.112383","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:29:59Z","timestamp":1717576199000},"page":"112383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-\u03b1 and IL-17A, in autoimmune disease models"],"prefix":"10.1016","volume":"136","author":[{"given":"Zhihang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-9137","authenticated-orcid":false,"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112383_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.112383_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2024.112383_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112383_b0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.112383_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112383_b0030","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.112383_b0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2024.112383_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.112383_b0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.crohns.2008.05.011","article-title":"Management of loss of response to anti-TNF drugs: change the dose or change the drug?","volume":"2","author":"Van Assche","year":"2008","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.intimp.2024.112383_b0050","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","volume":"64","author":"McGovern","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.112383_b0055","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/keq224","article-title":"Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression","volume":"49","author":"Aerts","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2024.112383_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/ar3431","article-title":"Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"13","author":"Chen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.112383_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications","author":"von Stebut","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112383_b0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/ITT.S240891","article-title":"The role of IL-17 cytokines in psoriasis","volume":"10","author":"Mosca","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.intimp.2024.112383_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010035","article-title":"The clinical significance of simultaneous IL-17A and IL-17F blockade in psoriasis non-responding to anti-IL17A therapy","volume":"12","author":"Kokolakis","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.112383_b0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijpharm.2018.05.058","article-title":"A novel fusion protein attenuates collagen-induced arthritis by targeting interleukin 17A and tumor necrosis factor alpha","volume":"547","author":"Liu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2024.112383_b0085","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.biopha.2018.09.178","article-title":"Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor \u03b1 on imiquimod-induced psoriasis in mice","volume":"108","author":"Liu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.112383_b0090","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1770018","article-title":"Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A","author":"Zheng","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2024.112383_b0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcph.1393","article-title":"Pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of JNJ-61178104, a novel tumor necrosis factor-alpha and Interleukin-17A bispecific antibody, in healthy subjects","volume":"59","author":"Akpalu","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112383_b0100","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2024.112383_b0105","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2024.112383_b0110","article-title":"R409K mutation prevents acid-induced aggregation of human IgG4","volume":"15","author":"Mallela","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112383_b0115","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1779974","article-title":"Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region","author":"Handlogten","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2024.112383_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000495291","article-title":"Psoriasis: keratinocytes or immune cells \u2013 which is the trigger?","volume":"235","author":"Benhadou","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.intimp.2024.112383_b0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.112383_b0130","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/MIB.0000000000000121","article-title":"IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-alpha-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes","volume":"20","author":"Friedrich","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.112383_b0135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bcp.2012.12.002","article-title":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin","volume":"85","author":"Tao","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112383_b0140","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2024.112383_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132905","article-title":"Bone metabolism and RANKL\/OPG ratio in rheumatoid arthritis women treated with TNF-\u03b1 inhibitors","volume":"10","author":"Jura-P\u00f3\u0142torak","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.112383_b0150","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.112383_b0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/art.38246","article-title":"Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis","volume":"66","author":"Thiolat","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.112383_b0160","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor\u2013 and Interleukin-17A\u2013targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.112383_b0165","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-021-00642-5","article-title":"Immunogenicity risk assessment for multi-specific therapeutics","volume":"23","author":"Kroenke","year":"2021","journal-title":"AAPS J."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:36:29Z","timestamp":1791300989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"alternative-id":["S1567576924009032"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112383","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-\u03b1 and IL-17A, in autoimmune disease models","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112383"}}